Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
ARCHIVE: MDB Capital CEO and Invizyne board member, Chris Marlett, presents the Invizyne story and initial public offering (IPO) opportunity to investors via Zoom on June 11, 2024
investorvideoARCHIVE
ARCHIVE: MDB Capital CEO and Invizyne board member, Chris Marlett, presents the Invizyne story and initial public offering (IPO) opportunity to investors via Zoom on June 11, 2024June 11, 2024
ARCHIVE: The story of eXoZymes: Interview with Tyler Korman and Paul Opgenorth
videoscienceARCHIVE
ARCHIVE: The story of eXoZymes: Interview with Tyler Korman and Paul OpgenorthMay 22, 2024
ARCHIVE: Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
talentpress releaseARCHIVE
ARCHIVE: Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on NasdaqMay 7, 2024
ARCHIVE: Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on NasdaqFebruary 12, 2024
ARCHIVE: Michael Burns Joins Invizyne as Executive Vice President of Energy Transition
talentbiofuelARCHIVE
ARCHIVE: Michael Burns Joins Invizyne as Executive Vice President of Energy TransitionNovember 8, 2023
ARCHIVE: Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth Cohort
biofuelpress releaseARCHIVE
ARCHIVE: Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth CohortOctober 17, 2023
Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy
biofuelpress release
Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of EnergyOctober 11, 2023
ARCHIVE: A bio-inspired cell-free system for cannabinoid production from inexpensive inputs
sciencepublicationARCHIVE
ARCHIVE: A bio-inspired cell-free system for cannabinoid production from inexpensive inputsAugust 24, 2020
ARCHIVE: Synthetic Biochemistry: The Bio-inspired Cell-Free Approach to Commodity Chemical Production
sciencepublicationARCHIVE
ARCHIVE: Synthetic Biochemistry: The Bio-inspired Cell-Free Approach to Commodity Chemical ProductionJuly 1, 2020
ARCHIVE: A cell-free platform for the prenylation of natural products and application to cannabinoid production
sciencepublicationARCHIVE
ARCHIVE: A cell-free platform for the prenylation of natural products and application to cannabinoid productionFebruary 4, 2019
Previous page
Page 10 of 11
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark